|
Patent landscape, scope, and claims summary: |
Executive summary
US Patent 10,059,762 centers on an “activatable” EGFR-binding antibody construct where an EGFR-binding antibody (including specified EGFR antibodies such as cetuximab) is masked by a short masking peptide (MM) that blocks EGFR binding in an uncleaved state, and is unmasked after protease cleavage of a polypeptide cleavable moiety (CM) that functions as a protease substrate. The claims are drafted with broad functional coverage (any EGFR-specific AB plus “MM comprises” specified sequence set and “CM is a protease substrate”) and with multiple nested specificity layers (exact MM sequences, exact CM substrate motifs, optional linking peptide architectures, AB identity lists, binding potency cap, and optional payload conjugation). This structure creates (i) strong coverage against close design-arounds that retain the same MM sequence set and protease-substrate logic and (ii) large clearances for competitors to evade by switching MM outside the listed sequence set, switching AB outside EGFR-specific parameters without using the claimed MM/CM logic, or using alternative masking/unmasking mechanisms not tied to the claimed “CM polypeptide protease substrate” formulation.
What claims does US 10,059,762 cover at a glance?
Core claim 1 is the keystone and reads as:
- Activatable antibody with AB that specifically binds EGFR (AB can be full IgG or an antigen-binding fragment).
- Masking moiety (MM) coupled to AB that in the uncleaved state inhibits EGFR binding.
- MM sequence limitation: MM comprises an amino acid sequence selected from a defined group that includes SEQ ID NO: 1 and ranges including 218-220, 236-265, and 266 (your excerpt lists example MM sequences such as SEQ ID NO: 1 = CISPRGC, plus downstream claim fallbacks).
- Cleavable moiety (CM) coupled to AB that is a polypeptide substrate for a protease, such that cleavage occurs to enable binding.
- Downstream claims add: exact MM sequences (claims 2-3), explicit functional performance thresholds (claim 6), specific protease classes and enzyme examples (claims 7, 9-12), structural architectures and linkers (claims 13-22), potency and format limitations (claims 23-24), and explicit AB identity lists including cetuximab (claims 25-26), plus payload conjugation (claims 28-35), plus nucleic acids/vectors and production method claims (claims 39-41).
How strong are the claim elements of US 10,059,762 for an EGFR “activatable antibody” portfolio?
Which claim features create the largest infringement “hook”?
-
The masked-uncleaved / unmasked-cleaved functional switch (claims 1, 4, 6, 13)
- Claim 1 requires that MM inhibits AB binding in an uncleaved state.
- Claim 4 narrows to the cleaved state by requiring MM does not interfere/compete with AB binding post-cleavage.
- Claim 6 hardens the functional scope with a quantitative benchmark: MM reduces EGFR binding by at least 90% in vitro (target displacement assay) when CM is uncleaved versus cleaved.
-
MM sequence-set limitation (claims 1, 2-3, plus multiple dependent claims specifying MM = CISPRGC or other CISPR-containing or listed sequences)
- The MM is not merely “a masking peptide” but is constrained to a defined set of amino acid sequences and ranges in the specification’s SEQ ID list.
- This is the most important design-around lever for competitors. If a competitor changes the MM sequence outside the claimed set, they can often avoid literal infringement even if the mechanism is similar.
-
CM as a protease-substrate polypeptide with enumerated sequence motifs (claims 1, 8-12)
- Claim 9 ties CM to Table 3 enzyme list; claim 10 lists uPA, legumain, matriptase, and MMP.
- Claim 11 enumerates CM motif sequences by SEQ ID numbers (267, 268, … 369).
- Claim 12 specifies one motif LSGRSDNH (SEQ ID NO: 271).
- This creates a second major design-around lever: change the CM cleavage motif so it does not fall within the listed CM substrate sequences.
-
Protease localization concept (claim 7)
- Claim 7 adds a contextual limitation that cleavage occurs when the antibody is exposed to a protease that is co-localized with EGFR in tissue.
- Depending on enforcement posture, this can be used to argue non-infringement if a competitor uses the same construct but targets a context lacking such co-localization (or if the construct does not rely on that localization).
What does the claim not require (space for non-infringing alternatives)?
- Claim 1 does not require a specific antibody format beyond antigen binding fragments and a set of AB types (later claims specify formats and AB identities).
- It does not require a specific linker chemistry in claim 1; linker structures are covered in dependent claims (claims 14-21).
- It does not require a specific payload by default; payload is optional (claims 28-35).
- It does not require a specific protease identity in claim 1; it requires CM to be a protease substrate, with enzyme examples and motif enumerations provided in dependent claims.
Practical inference for freedom-to-operate (FTO): A competitor is most at risk if they use EGFR-binding antibodies combined with (i) MM sequences in the claimed set and (ii) CM cleavage motifs that are in the enumerated set (or at least function as substrates for one of the enumerated enzyme classes with corresponding motifs). Risk drops materially if they shift either MM sequence or CM motif out of the claim-defined enumerations.
Which MM (masking moiety) sequences and CM (cleavable moiety) motifs are expressly protected?
MM sequences
The excerpt identifies:
- Claim 2: MM comprises CISPRGC (SEQ ID NO: 1)
- Claim 3: MM comprises CISPRGCPDGPYVM (SEQ ID NO: 218) or CISPRGCPDGPYVMY (SEQ ID NO: 238)
- Claim 22: MM comprises CISPRGC (SEQ ID NO: 1)
- Claim 1: MM comprises a sequence selected from a group including SEQ ID NO: 1 and other SEQ ranges 218-220, 236-265, 266
Because the full SEQ ID list is not reproduced here, the enforceable literal scope is restricted to the sequence-set recited in the claims and dependent claims. The MM is not generic; it is enumerated by SEQ ID selection.
CM sequences and protease substrates
The excerpt identifies:
- Claim 8: CM polypeptide up to 15 amino acids
- Claim 10: CM substrate for enzymes in the group including uPA, legumain, matriptase, and MMP
- Claim 11: CM amino acid sequences selected from SEQ ID set including
- TGRGPSWV (SEQ ID NO: 267)
- SARGPSRW (SEQ ID NO: 268)
- TARGPSFK (SEQ ID NO: 269)
- TARGPSW (SEQ ID NO: 270)
- LSGRSDNH (SEQ ID NO: 271)
- GGWHTGRN (SEQ ID NO: 272)
- HTGRSGAL (SEQ ID NO: 273)
- PLTGRSGG (SEQ ID NO: 274)
- LTGRSGA (SEQ ID NO: 275)
- AARGPAIH (SEQ ID NO: 276)
- RGPAFNPM (SEQ ID NO: 277)
- SSRGPAYL (SEQ ID NO: 278)
- RGPATPIM (SEQ ID NO: 279)
- RGPA (SEQ ID NO: 280)
- GLSGRSDNHGSS (SEQ ID NO: 366)
- PLTGRSGGGGSS (SEQ ID NO: 367)
- ETPSVKTMGRSS (SEQ ID NO: 368)
- GTGRGPSWVGSS (SEQ ID NO: 369)
- Claim 12: CM comprises LSGRSDNH (SEQ ID NO: 271)
Practical enforcement effect: For literal infringement, a product with CM motifs not matching the listed SEQ ID sequences likely avoids dependent claim coverage (claims 11-12, and enzyme-specific combinations that rely on those motifs). The broader claim 1 may still capture equivalents via “CM functions as a substrate for a protease,” but the presence of sequence enumeration in dependent claims will matter in claim construction and obviousness/validity challenges.
What EGFR antibodies are named, and what does that do to commercial risk?
AB identity list creates direct “named defendant” pressure
Claims 25-26 expressly name EGFR antibodies and/or fragments:
- Claim 25: AB is one of: cetuximab, panitumumab, zalutumumab, matuzumab, nimotuzumab, ICR62, mAb 528, CH806, MDX447, or fragments
- Claim 26: AB is cetuximab or a fragment
How does this affect infringement strategy?
- If an accused product uses cetuximab (or a cetuximab-derived binding fragment) plus a matching MM and CM logic, it can fall into narrow dependent claim 26.
- If a product uses a different EGFR antibody not in the list, it can still be within claim 1 if it “specifically binds to EGFR,” but it will lose the advantages of named-AB dependencies (claims 25-26).
Commercial implication: Named antibodies increase settlement leverage because defendants face more direct claim-to-product mapping in litigation, especially when manufacturing and design documentation show the parental AB is one of the listed antibodies.
When does the masking fail and binding succeed, according to the claims?
Cleavage-dependent binding restoration is built into the claim set
- Claim 4: MM does not interfere or compete with AB for EGFR binding in a cleaved state.
- Claim 6: in vitro, uncleaved MM reduces binding by ≥90% versus cleaved.
- Claim 13: uncleaved arrangement is specified as MM-CM-AB or AB-CM-MM (N- to C-terminal order).
Why this matters for design-arounds
Competitors can try to keep an “activatable” effect but avoid the claim’s architecture:
- Altering terminal ordering (MM-CM-AB or AB-CM-MM) could evade claim 13 dependent coverage.
- Using uncleaved constructs that do not meet the ≥90% binding reduction threshold (claim 6) could evade those dependent claims even if the mechanism is conceptually similar.
What linkage and architecture variants are covered beyond MM-CM-AB?
Linker and dual-linker architectures
- Claim 14: linker between MM and CM
- Claim 15: linker between CM and AB
- Claim 16: introduces dual linking peptides LP1 and LP2 with uncleaved arrangement:
- MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM
- Claim 19-21: LP1 and/or LP2 sequences restricted to repeated glycine/serine motifs such as (GS)n, (GGS)n, (GSGGS)n, (GGGS)n and specific examples including GGSGGS (SEQ ID NO: 111) and “GS or GSSG” options.
Infringement effect: The base mechanical concept (MM + protease-cleavable CM + EGFR AB) is protected at claim 1 level. Dependent claims then create additional “tight” coverage for specific architectures and gly/ser repeat linkers. Products using different linker chemistry or different linker lengths outside the recited categories can avoid dependent coverage.
How do payload-conjugation claims expand patent coverage into ADC-like commercial products?
Antibody conjugated to an agent
- Claim 28: AB conjugated to an agent
- Claim 29-30: agent can be therapeutic and antineoplastic
- Claim 31: agent is a toxin or fragment
- Claim 32: agent is selected from “agents in Table 4”
- Claim 33: agent conjugated via a linker
- Claim 34-35: linker can be cleavable or non-cleavable
What this enables
These claims push coverage beyond “naked activatable antibodies” into constructs where the activatable EGFR-binding module is combined with a cytotoxic payload. In practice, this can collide with licensing and development programs that position these constructs as drug conjugates (including toxin conjugates that are not necessarily classical ADCs).
What do the nucleic acid, vector, and production method claims cover?
- Claim 39: isolated nucleic acid molecule encoding the activatable antibody of claim 1
- Claim 40: vector comprising the nucleic acid
- Claim 41: method of producing an activatable antibody by culturing a cell under conditions leading to expression, where the cell contains the vector
Enforcement leverage: These claims are often used to support discovery and to capture manufacturing workflows in litigation, particularly where cell lines, plasmids, or expression constructs are involved.
What patents, exclusivity, and regulatory status affect the US competitive landscape around US 10,059,762?
Insufficient information to complete a patent-landscape synthesis.
A comprehensive analysis requires: (i) the patent’s bibliographic details (assignee, filing dates, priority claims, and expiration timeline), (ii) the full claims set and specification disclosure context, (iii) the Orange Book entries for relevant EGFR activatable antibody or conjugate products, and (iv) the list of family members and related continuation/divisional patents. None of those are provided here, and the question requests a comprehensive critical landscape analysis that depends on those missing facts.
No landscape can be produced without risking fabricated citations or incorrect legal timelines, so none is included.
Key Takeaways
- US 10,059,762 claim 1 is anchored by an EGFR-binding antibody whose binding is suppressed in an uncleaved state by an enumerated MM sequence set and restored after protease cleavage of an enumerated CM polypeptide substrate motif set.
- Literal infringement risk is highest where both MM sequence and CM substrate motif fall within the claimed enumerations and where the product meets the ≥90% uncleaved binding reduction benchmark (claim 6) and the cleaved-state non-interference requirement (claim 4).
- Dependent claims tighten coverage for specific EGFR antibodies (including cetuximab), specific protease classes (uPA, legumain, matriptase, MMP), and specific linker/architecture arrangements (MM-CM-AB / AB-CM-MM and dual gly/ser linker motifs).
- Payload conjugation and manufacturing claims broaden the commercial target beyond binding biology into conjugate formats and expression systems.
FAQs
- What design changes most reliably avoid claim 1’s MM-based masking limitations?
- How do the enumerated CM substrate SEQ ID motifs in claims 11-12 affect literal infringement versus functional equivalence arguments?
- Does using a non-listed EGFR antibody format still risk claim 1 infringement under the “specifically binds EGFR” requirement?
- How do uncleaved binding suppression thresholds (claim 6) influence product testing and litigation evidence?
- Which manufacturing steps most often implicate the nucleic acid/vector and production method claims (claims 39-41)?
References (APA)
No sources were cited because no bibliographic or external records for US 10,059,762 were provided.
More… ↓
⤷ Start Trial
|
